Merck revenue falls after dramatic drop in sales of Covid antiviral treatment

Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for Q1 2023 beat Wall Street's expectations.

from Health and Science https://ift.tt/hCRVPuH
https://ift.tt/fuFmXTC
https://ift.tt/c3Q2JXS